Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal
https://www.zacks.com/stock/news/2269766/quest-diagnostics-dgx-grows-in-digital-pathology-with-new-deal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2269766
May 07, 2024 - Quest Diagnostics' (DGX) pathology laboratories nationwide are set to get a boost with PathAI's AISight digital pathology image management system.
0
Here's Why You Should Hold Lantheus (LNTH) in Your Portfolio Now
https://www.zacks.com/stock/news/2265409/here-s-why-you-should-hold-lantheus-lnth-in-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2265409
Apr 30, 2024 - Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
0
Factors Setting the Tone for Ecolab's (ECL) Q1 Earnings
https://www.zacks.com/stock/news/2263587/factors-setting-the-tone-for-ecolab-s-ecl-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2263587
Apr 26, 2024 - Ecolab's (ECL) first-quarter results are likely to reflect continued segmental strength.
0
Agnico Eagle's (AEM) Q1 Earnings and Sales Beat Estimates
https://www.zacks.com/stock/news/2263531/agnico-eagle-s-aem-q1-earnings-and-sales-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2263531
Apr 26, 2024 - Agnico Eagle's (AEM) first-quarter earnings and revenues exceed expectations, driven by increased production and higher realized gold prices.
0
Newmont's (NEM) Q1 Earnings and Revenues Beat Estimates
https://www.zacks.com/stock/news/2262672/newmont-s-nem-q1-earnings-and-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2262672
Apr 25, 2024 - Newmont's (NEM) first-quarter earnings and revenues exceed expectations, driven by increased production and higher realized gold prices.
0
Revvity's (RVTY) New Launch to Boost Tuberculosis Testing
https://www.zacks.com/stock/news/2262625/revvity-s-rvty-new-launch-to-boost-tuberculosis-testing?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2262625
Apr 25, 2024 - Revvity's (RVTY) latest offering is likely to provide a new and improved workflow to lower hands-on time and enable increased lab productivity.
0
Penumbra's (PEN) New Launch to Enhance Blood Clot Removal
https://www.zacks.com/stock/news/2261445/penumbra-s-pen-new-launch-to-enhance-blood-clot-removal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2261445
Apr 24, 2024 - Penumbra's (PEN) latest offering is likely to enable physicians to restore blood flow more quickly and further minimize blood loss.
0
Reasons Why You Should Retain HealthEquity (HQY) Stock for Now
https://www.zacks.com/stock/news/2260548/reasons-why-you-should-retain-healthequity-hqy-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2260548
Apr 23, 2024 - HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
0
GE HealthCare's (GEHC) New Tie-Up to Boost Patient Outcomes
https://www.zacks.com/stock/news/2260545/ge-healthcare-s-gehc-new-tie-up-to-boost-patient-outcomes?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2260545
Apr 23, 2024 - GE HealthCare's (GEHC) latest partnership is likely to benefit global healthcare systems by enhancing Elekta's RT offerings with its MIM Software medical imaging management solutions.
0
3 Dividend Aristocrats to Take the Edge off Market Volatility
https://www.zacks.com/stock/news/2259379/3-dividend-aristocrats-to-take-the-edge-off-market-volatility?cid=CS-ZC-FT-analyst_blog|investment_ideas-2259379
Apr 22, 2024 - With markets remaining topsy-turvy, it's prudent for astute investors to pick dividend aristocrats like Atmos Energy (ATO), Ecolab (ECL) and SherwinWilliams (SHW) for steady income.
0